Facts: Why Institutions and Commons Are Still Buying This Stock...Simple...Its More To Come!!
It's not just the recent approval but whatever Celgene gets FDA approval for that came about from the Abraxis deal. Abraxane has many other cancer uses that are in the pipleline, plus other products in the pipeline. I wish I could attach a link but please do your own DD you will see Investment written all over this CVR. Key words below...Abraxane and the other Products. Quote from Investor Village article: "Additional royalty payments could ensue if Abraxane and certain other Abraxis pipeline products meet as-yet-undisclosed net revenue targets". That is why people are still buying this investment CVR.
Net Sales Payments. For each full one-year period ending December 31 during the term of the CVR Agreement (a “Net Sales Measuring Period ending on December 31, 2025), Celgene will be obligated to pay to the CVR holders:
2.5% of that portion of Net Sales of Abraxane® and the other Products (as each such term is defined in the CVR Agreement) that exceeds $1 billion but is less than or equal to $2 billion for such period, plus
an additional amount equal to 5.0% of that portion of Net Sales of Abraxane® and the other Products that exceeds $2 billion but is less than or equal to $3 billion for such period, plus
an additional amount equal to 10.0% of that portion of Net Sales of Abraxane® and the other Products that exceeds $3 billion for such period